News | August 10, 2024
Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
Expect the international business including CDMO business to pick-up in the second half of the financial year
Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Subscribe To Our Newsletter & Stay Updated
